PALISADE BIO, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
PALISADE BIO, INC. (PALI) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $4.79 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-10
- PALISADE BIO, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $4.79M, a 6834.78% increase year-over-year.
- PALISADE BIO, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $4.30M, a 6127.54% increase year-over-year.
- PALISADE BIO, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-12-31 was $3.77M, a 4796.10% increase year-over-year.
- PALISADE BIO, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $47.00K, a 50.53% decline year-over-year.
- PALISADE BIO, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $3.96M, a 506.60% increase from fiscal 2024.
- PALISADE BIO, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $652.00K, a 4.49% increase from fiscal 2023.
- PALISADE BIO, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $624.00K, a 39.53% decline from fiscal 2022.
- PALISADE BIO, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $1.03M, a 45.43% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $4.79M 10-Q · filed 2026-08-10 | $9.08M 10-Q · filed 2026-08-10 | $12.85M derived: sum of 3 quarters · filed 2026-08-10 | $12.90M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2026-03-31 | $4.30M 10-Q · filed 2026-05-12 | $8.07M derived: sum of 2 quarters · filed 2026-05-12 | $8.11M derived: sum of 3 quarters · filed 2026-05-12 | $8.18M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2025-12-31 | $3.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-20 | $3.82M derived: sum of 2 quarters · filed 2026-03-20 | $3.89M derived: sum of 3 quarters · filed 2026-08-10 | $3.96M 10-K · filed 2026-03-20 | ||
| 2025-09-30 | $47.00K 10-Q · filed 2025-11-10 | $116.00K derived: sum of 2 quarters · filed 2026-08-10 | $185.00K 10-Q · filed 2025-11-10 | $262.00K derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2025-06-30 | $69.00K 10-Q · filed 2026-08-10 | $138.00K 10-Q · filed 2026-08-10 | $215.00K derived: sum of 3 quarters · filed 2026-08-10 | $310.00K derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2025-03-31 | $69.00K 10-Q · filed 2026-05-12 | $146.00K derived: sum of 2 quarters · filed 2026-05-12 | $241.00K derived: sum of 3 quarters · filed 2026-05-12 | $603.00K derived: sum of 4 quarters · filed 2026-05-12 | ||
| 2024-12-31 | $77.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-20 | $172.00K derived: sum of 2 quarters · filed 2026-03-20 | $534.00K derived: sum of 3 quarters · filed 2026-03-20 | $652.00K 10-K · filed 2026-03-20 | ||
| 2024-09-30 | $95.00K 10-Q · filed 2025-11-10 | $457.00K derived: sum of 2 quarters · filed 2025-11-10 | $575.00K 10-Q · filed 2025-11-10 | $760.00K derived: sum of 4 quarters · filed 2025-11-10 | ||
| 2024-06-30 | $362.00K 10-Q · filed 2025-08-11 | $480.00K 10-Q · filed 2025-08-11 | $665.00K derived: sum of 3 quarters · filed 2025-08-11 | $867.00K derived: sum of 4 quarters · filed 2025-08-11 | ||
| 2024-03-31 | $118.00K 10-Q · filed 2025-05-12 | $303.00K derived: sum of 2 quarters · filed 2025-05-12 | $505.00K derived: sum of 3 quarters · filed 2025-05-12 | $649.00K derived: sum of 4 quarters · filed 2025-05-12 | ||
| 2023-12-31 | $185.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $387.00K derived: sum of 2 quarters · filed 2025-03-24 | $531.00K derived: sum of 3 quarters · filed 2025-03-24 | $624.00K 10-K · filed 2025-03-24 | ||
| 2023-09-30 | $202.00K 10-Q · filed 2024-11-12 | $346.00K derived: sum of 2 quarters · filed 2024-11-12 | $439.00K 10-Q · filed 2024-11-12 | $525.00K derived: sum of 4 quarters · filed 2024-11-12 | ||
| 2023-06-30 | $144.00K 10-Q · filed 2023-08-10 | $237.00K 10-Q · filed 2024-08-12 | $323.00K derived: sum of 3 quarters · filed 2024-05-13 | $575.00K derived: sum of 4 quarters · filed 2024-05-13 | ||
| 2023-03-31 | $93.00K 10-Q · filed 2024-05-13 | $179.00K derived: sum of 2 quarters · filed 2024-05-13 | $431.00K derived: sum of 3 quarters · filed 2024-05-13 | $767.00K derived: sum of 4 quarters · filed 2024-05-13 | ||
| 2022-12-31 | $86.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $338.00K derived: sum of 2 quarters · filed 2024-03-26 | $674.00K derived: sum of 3 quarters · filed 2024-03-26 | $1.03M 10-K · filed 2024-03-26 | ||
| 2022-09-30 | $252.00K 10-Q · filed 2023-11-09 | $588.00K derived: sum of 2 quarters · filed 2023-11-09 | $946.00K 10-Q · filed 2023-11-09 | $1.63M derived: sum of 4 quarters · filed 2023-11-09 | ||
| 2022-06-30 | $336.00K 10-Q · filed 2023-08-10 | $694.00K 10-Q · filed 2023-08-10 | $1.38M derived: sum of 3 quarters · filed 2023-08-10 | $1.48M derived: sum of 4 quarters · filed 2023-08-10 | ||
| 2022-03-31 | $358.00K 10-Q · filed 2023-05-11 | $1.04M derived: sum of 2 quarters · filed 2023-05-11 | $1.14M derived: sum of 3 quarters · filed 2023-05-11 | $1.64M derived: sum of 4 quarters · filed 2023-05-11 | ||
| 2021-12-31 | $683.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $786.00K derived: sum of 2 quarters · filed 2023-03-22 | $1.28M derived: sum of 3 quarters · filed 2023-03-22 | $1.89M 10-K · filed 2023-03-22 | ||
| 2021-09-30 | $103.00K 10-Q · filed 2022-11-14 | $598.00K derived: sum of 2 quarters · filed 2022-11-14 | $1.21M 10-Q · filed 2022-11-14 | $1.64M derived: sum of 4 quarters · filed 2022-11-14 | ||
| 2021-06-30 | $495.00K 10-Q · filed 2022-08-15 | $1.06M 10-Q · filed 2022-08-15 | $1.53M derived: sum of 3 quarters · filed 2022-08-15 | $2.20M derived: sum of 4 quarters · filed 2022-08-15 | ||
| 2021-03-31 | $569.00K 10-Q · filed 2022-05-13 | $247.99K 10-Q · filed 2021-05-14 | $1.04M derived: sum of 2 quarters · filed 2022-05-13 | $1.70M derived: sum of 3 quarters · filed 2022-05-13 | $2.10M derived: sum of 4 quarters · filed 2022-05-13 | |
| 2020-12-31 | $470.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $1.13M derived: sum of 2 quarters · filed 2022-03-17 | $1.53M derived: sum of 3 quarters · filed 2022-03-17 | $2.01M 10-K · filed 2022-03-17 | $584.99K 10-K · filed 2021-03-22 | |
| 2020-09-30 | $664.00K 10-Q · filed 2021-11-12 | $206.82K 10-Q · filed 2020-11-10 | $1.06M derived: sum of 2 quarters · filed 2021-11-12 | $1.54M 10-Q · filed 2021-11-12 | ||
| 2020-06-30 | $393.00K 10-Q · filed 2021-08-23 | $241.25K 10-Q · filed 2020-08-13 | $880.00K derived: sum of 2 quarters · filed 2021-08-23 | |||
| 2020-03-31 | $487.00K 10-Q · filed 2021-08-23 | $75.89K 10-Q · filed 2020-05-15 | ||||
| 2019-12-31 | $880.79K 10-K · filed 2021-03-22 | |||||
| 2019-09-30 | $294.60K 10-Q · filed 2020-11-10 | $423.38K derived: sum of 2 quarters · filed 2020-11-10 | $761.34K derived: sum of 3 quarters · filed 2020-11-10 | |||
| 2019-06-30 | $128.78K 10-Q · filed 2020-11-10 | $466.74K derived: sum of 2 quarters · filed 2020-11-10 | ||||
| 2019-03-31 | $337.97K 10-Q · filed 2020-11-10 | |||||
| 2018-12-31 | $634.08K 10-K · filed 2020-03-27 | |||||
| 2018-09-30 | $134.70K 10-Q · filed 2019-11-14 | $331.44K derived: sum of 2 quarters · filed 2019-11-14 | $570.27K derived: sum of 3 quarters · filed 2019-11-14 | |||
| 2018-06-30 | $196.74K 10-Q · filed 2019-11-14 | $435.58K derived: sum of 2 quarters · filed 2019-11-14 | ||||
| 2018-03-31 | $238.84K 10-Q · filed 2019-11-14 | |||||
| 2017-12-31 | $1.77M 10-K · filed 2019-03-22 | |||||
| 2016-12-31 | $3.45M 10-K · filed 2018-04-02 | |||||
| 2015-12-31 | $2.95M 10-K · filed 2017-03-23 | |||||
| 2014-12-31 | $4.32M 10-K · filed 2016-03-14 | |||||
| 2013-12-31 | $1.67M 10-K · filed 2016-03-14 | |||||
| 2012-12-31 | $1.37M 10-K · filed 2015-03-16 | |||||
| 2011-12-31 | $313.90K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-10 | $837.01K derived: sum of 2 quarters · filed 2014-03-10 | $2.92M 10-K · filed 2014-03-10 | |||
| 2011-09-30 | $523.12K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2011-11-09 | $2.61M 10-Q · filed 2011-11-09 | ||||
| 2011-06-30 | $2.09M 10-Q/A · filed 2011-09-23 | |||||
| 2010-12-31 | $4.92M 10-K · filed 2012-03-30 | |||||
| 2009-12-31 | $4.56M 10-K · filed 2012-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |